Discussion stirs around Chiasma, Inc. (NASDAQ:CHMA) this week; here is what analysts are saying.

Chiasma, Inc. (NASDAQ:CHMA) Logo

Chiasma, Inc. (NASDAQ:CHMA) Ratings Coverage

Among 2 analysts covering Chiasma (NASDAQ:CHMA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Chiasma had 4 analyst reports since February 14, 2019 according to SRatingsIntel. The stock of Chiasma, Inc. (NASDAQ:CHMA) earned “Buy” rating by H.C. Wainwright on Friday, March 8. As per Tuesday, February 19, the company rating was initiated by Roth Capital. Below is a list of Chiasma, Inc. (NASDAQ:CHMA) latest ratings and price target changes.

08/03/2019 Broker: H.C. Wainwright Rating: Buy New Target: $11 Maintain
07/03/2019 Broker: Cantor Fitzgerald Rating: Overweight Initiates Coverage On
19/02/2019 Broker: Roth Capital Rating: Buy New Target: $16 Initiate
14/02/2019 Broker: H.C. Wainwright Rating: Buy New Target: $11 Initiates Coverage On

The stock increased 1.54% or $0.1 during the last trading session, reaching $6.59. About 259,210 shares traded or 155.34% up from the average. Chiasma, Inc. (NASDAQ:CHMA) has risen 206.45% since March 17, 2018 and is uptrending. It has outperformed by 202.08% the S&P500.

Chiasma, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies using transient permeability enhancer technology platform. The company has market cap of $161.23 million. The firm offers octreotide capsules, which is in Phase III clinical trial for the treatment of acromegaly, a condition that results in the bodyÂ’s production of excess growth hormone under the MYCAPSSA name. It currently has negative earnings.

More notable recent Chiasma, Inc. (NASDAQ:CHMA) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: Allergan’s Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO – Benzinga” on March 07, 2019, also Benzinga.com with their article: “Daily Biotech Pulse: Zafgen Won’t File IND For Metabolic Disorder Drug, Positive Results For Akebia’s Anemia Drug – Benzinga” published on March 12, 2019, Globenewswire.com published: “Chiasma to Participate in Three Investor Conferences in March – GlobeNewswire” on March 04, 2019. More interesting news about Chiasma, Inc. (NASDAQ:CHMA) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For March 7, 2019 – Benzinga” published on March 07, 2019 as well as Seekingalpha.com‘s news article titled: “Chiasma up 15% ahead of Q4 report – Seeking Alpha” with publication date: March 05, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.